Skip to main content
About

Challenge 2030

According to the World Health Organization (WHO), COPD is projected to become the world’s third leading cause of death in 2030. Boehringer Ingelheim is proud to lead an initiative to highlight and address the current challenges in the management of COPD with the intention of reducing the burden on patients, clinicians and nations.

Working collaboratively, Boehringer Ingelheim and the medical community can drive improvements in COPD management through insight-driven medical education.

Boehringer Ingelheim is launching a medical education initiative that will challenge the five priority areas where COPD management and care can be addressed:

  • (Secondary) Prevention
  • Early and Accurate Diagnosis
  • Treatment Approaches
  • Holistic Patient Management
  • Supporting Patient - Physician Partnerships

Disclaimer

Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.

Continue

Welcome to RespiratoryXchange for international healthcare professionals outside the United States of America.

This website is an international information resource intended for international healthcare professionals outside the United States of America (US) who are interested in medical information on respiratory diseases such as COPD.

While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that the registration status and approved product labels of the mentioned medicinal products may not be the same in different countries. Please refer to your local prescribing information for full details on the respective medicinal products.

By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and have read and understood this disclaimer.

I accept Leave website Go to website for healthcare professionals in the US